What question did this study set out to answer?

The study aims to identify barriers to the implementation of long-acting HIV prevention methods in large populations.

April 23, 2026Open Access

Challenges facing long-acting PrEP implementation in large populations

Key Points

The study aims to identify barriers to the implementation of long-acting HIV prevention methods in large populations.
Analyzed long-acting formulations of lenacapavir as a new prevention strategy.
Evaluated adherence issues related to daily oral PrEP.
Explored the implications for populations with high HIV incidence.
Long-acting injectable lenacapavir improves adherence compared to daily oral PrEP.
Identifiable challenges remain in implementing long-acting PrEP in specific populations.
The formulation is particularly beneficial in areas with high rates of HIV transmission.

Abstract

The introduction of long-acting antiviral prophylaxis drugs, exemplified by the twice-yearly injectable capsid inhibitor lenacapavir 1,2, marks a remarkable advance in HIV prevention, which address the adherence issue that has limited the real-world use of daily oral pre-exposure prophylaxis (PrEP) 3,4. The long-acting formulations of lenacapavir offer a potent prevention tool, particularly well-suited for countries where the HIV transmission mainly occurred in certain populations with high incidence.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper